Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0002050709-26-000029·Squadron Capital Management LLC
Schedule 13G ownership disclosure
Contineum Therapeutics Inc
Class A Common Stock, par value $0.001 per share · CUSIP: 21217B100
Event date: 2026-10-21
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Squadron Master Fund LP
Shares: 1,700,000.00 · Class: 5.1%
- Squadron Capital Management LLC
Shares: 1,700,000.00 · Class: 5.1%
- Matthew Sesterhenn
Shares: 1,700,000.00 · Class: 5.1%
- William Blank
Shares: 1,700,000.00 · Class: 5.1%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0002050709-26-000029
- Form type
- SCHEDULE 13G
- Filer
- Squadron Capital Management LLC
- CIK
- CIK 2050709
- Filed
- Oct 28, 2026
- Reporting period
- Oct 21, 2026
- Description
- Schedule 13G beneficial ownership